Core Viewpoint - The company Shenyuan Biotech (688098) announced the acquisition of a patent for a method to treat and functionally cure HIV infection using monoclonal antibodies targeting CD4 [1] Group 1 - The patent was granted by the National Intellectual Property Administration of China [1] - The invention relates to monoclonal antibodies targeting CD4, their compositions, and methods for using these compositions to prevent and treat HIV infection [1]